NCT02544750 2022-07-14An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)Jazz PharmaceuticalsPhase 3 Completed199 enrolled 14 charts